MegaDefense, NCD (Natural Cellular Defense), Waiora Scientist Rik Deitsch – Corporate Tax Liens – Board of Directors – Stan Cherelstein (Stanley J. Cherelstein)

Wellness Industries Tax Lien: http://sunbiz.org/pdf/08010341.pdf

Nutra Pharma Tax Liens:

– http://sunbiz.org/pdf/11019661.pdf

–  http://sunbiz.org/pdf/12001295.pdf

– http://sunbiz.org/scripts/liendet.exe?action=DETLIENBCOMPACT&web_dir=%20&web_key_number=12FLR0006548&web_key_seq=0001&web_return_number=11FLR0019661&web_return_seq=0001

Federal Lien Debtor Name Detail

Filing Information

Summary for Filing 12FLR0006548 Filings Completed Thru 06/12/2012 Date Filed 05/22/2012 Status ACTIVE Expires 05/23/2022 Pages in all Forms/Attachments 1 Current Secured Parties 1 Current Debtors 1 Events Filed NONE Serial Number 868028312 Assessment Date 04/23/2012

Secured Parties Address

IRS JACKSONVILLE P.O. BOX 35045 STOP 5750 ATTN: LIEN CLERK JACKSONVILLE, FL 322020045 US FEI/EIN Number: NONE

Debtor Parties Address

NUTRA PHARMA CORP 2776 N UNIVERSITY DR CORAL SPRINGS, FL 330655100 US FEI/EIN Number: 912021600

Who is on Nutra Pharma’s Board of Directors (http://www.nutrapharma.com/corporate_overview/board_of_directors.php)?

	Rik J. Deitsch Chairman and Chief Executive Officer Nutra Pharma CorporationRik J. Deitsch has been the President, Chief Executive Officer and a Director of the Company since November 7, 2002. From February 1998 through November 2002, Mr. Deitsch served as the President of NDA Consulting Inc., a biotechnology research group that provided consulting services to the pharmaceutical industry. NDA Consulting specialized in the research of peptides derived from Cone Snail venom, Cobra venom and Gila Monster venom. Mr. Deitsch holds both a B.S. in Chemistry and an M.S. in Biochemistry from Florida Atlantic University and has conducted clinical and laboratory research in collaboration with scientists at Duke University Medical Center and the Cleveland Clinic . Mr. Deitsch is an adjunct professor and teaches several courses for Florida Atlantic University’s College of Business and Continuing Education Department.
	Harold H. Rumph Interim President ReceptoPharm, Inc.Harold H. Rumph has been a Director of the Company since March of 2003 and brings with him a career devoted to technical sales and marketing. From 1988 to 2003 he was founder and owner of a high tech business providing computerized scheduling services to the construction industry. From 1986 to 1988, Mr. Rumph was Director of Sales and Marketing for JE Research, Inc. From 1980 to 1986 he was a founder, President, and Director of Biogenix, Inc. This company was involved in the development, manufacturing, and marketing of in-hospital bedside and ambulatory Patient Monitoring Systems. Biogenix was also involved with research and development of antiviral peptides from cobra venoms, including clinical trials under FDA-issued Investigational New Drug applications. Prior to the above Mr. Rumph led sales teams and was responsible for marketing at Harris Communications, Harris Computers, Memorex Corporation, Xerox Corporation, Cincinnati Milacron, Amdahl Corporation, RCA Computers, and IBM. Mr. Rumph received his BS degree from the United States Naval Academy.
	Dr. Stewart Lonky, MD DirectorDr. Lonky is board certified in internal medicine, pulmonary and critical care medicine. As a National Institutes of Health post doctoral fellow and faculty member at the University of California, San Diego, he spearheaded a research team studying the cellular and biochemical mechanisms of lung injury. He has published over a dozen articles in the peer-reviewed literature in this field. His practice involves the evaluation and treatment of patients with toxic exposures as well as patients with lung disease, and he has co-authored the book Invisible Killers, The truth about environmental genocide.From 1990-2006 he served as Chief Medical Officer of a medical device company that developed diagnostic products for the early diagnosis of cervical and oral cancer. In that role, his duties included the direction of clinical research and the ultimate clearance of three new diagnostic devices by the U.S. Food and Drug Administration (FDA). Dr. Lonky has published numerous articles in the peer-reviewed literature in the area of cellular physiology and its relation to cervical and oral cancer detection. Since Early 2007 he has been a Board Member of Histologix, LLC, a company that is bringing innovative biopsy tools to the medical marketplace. Dr. Lonky is specifically involved with the regulatory clearances of these novel devices for use on various tissue surfaces. Dr. Lonky earned his B.S. degree at St. Lawrence University, his M.D. from the State University of New York, Downstate, and his M.B.A. from Pepperdine University.
	Garry R. Pottruck DirectorGarry R. Pottruck, 53 years of age, has been a Principal in the accounting and consulting firm, Argy, Wiltse & Robinson, PC (“Argy”), headquartered in McLean, Virginia, since October 2005. From July 1997 through October 2005 when that company was acquired by Argy, he was managing partner in the certified public accounting firm, Friedberg & Pottruck, PA, located in Deerfield Beach, Florida. Friedberg & Pottruck specialized in providing accounting, tax and consulting services to physician practices.Mr. Pottruck held financial executive positions with several companies, both public and private, from 1984 through 1994, including more than three years as Chief Accounting Officer/Controller at Scopas Technology Company, Inc., a NASDAQ listed, development stage biotechnology research and development organization.Prior to 1984, Mr. Pottruck worked for public accounting firms after graduating with a B.S. Degree in Accounting from the C.W. Post School of Professional Accountancy at Long Island University in 1979. He is currently a member of both the Florida and American Institutes of Certified Public Accounting, and is licensed as a Certified Public Accountant in both Missouri and Florida.

Nutra Pharma Press Release: Stanley J Cherelstein has accepted a position on the Board effective September 28, 2004. – http://www.nutrapharma.com/newsroom/display.php?newsid=37

“I am very excited to be part of Nutra Pharma,” remarked Stanley J Cherelstein. “This is a great time for the Company and I hope to be able to make a strong, positive contribution as Nutra Pharma grows into the future,” he concluded.

“Stan’s background in accounting, sales and marketing adds necessary experience to the Board that will allow Nutra Pharma to move from its development stage into near-term revenues,” added Rik Deitsch.